RP23-418H15.1 Inhibitors
RP23-418H15.1 inhibitors refers to a class of chemical compounds designed to selectively bind to and inhibit the activity of a specific biological target identified by the genomic marker RP23-418H15.1. This marker is typically associated with a particular gene or protein that plays a role in a biochemical pathway within an organism. The inhibitors are synthesized following a deep understanding of the structure and function of this target, aiming to achieve a high degree of specificity to reduce the likelihood of off-target effects that can lead to unwanted interactions within the biological system. The development of such inhibitors involves extensive research in molecular biology, chemistry, and structural biology to understand the precise interaction between the inhibitor molecule and the target site.
Chemically, RP23-418H15.1 inhibitors can be diverse, encompassing a range of small molecules, peptides, or even antibody-like structures, each engineered to fit snugly into the active or binding site of the target. This fit is often likened to a lock and key mechanism, where the inhibitor must have the correct shape, charge distribution, and hydrophobic or hydrophilic properties to interact with the target site effectively. The design process frequently leverages computational methods, such as molecular docking and virtual screening, to predict how these inhibitors will interact with their target. Furthermore, the inhibitors may be designed to form reversible or irreversible interactions with their targets, with the specific choice depending on the desired outcome of the inhibition and the nature of the target itself. The fine-tuning of these molecular interactions is a sophisticated process that often requires iterative cycles of design, synthesis, and testing to optimize the inhibitors' efficacy and selectivity.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor, a kinase involved in the MAPK/ERK signaling pathway. By inhibiting MEK, PD98059 would reduce ERK activity, which could indirectly decrease the functional activity of RP23-418H15.1 if RP23-418H15.1 is a downstream effector in this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, blocking the PI3K/AKT/mTOR pathway. Inhibition of this pathway could lead to reduced phosphorylation and activation of downstream targets, potentially including RP23-418H15.1 if it is regulated by AKT or mTOR phosphorylation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor, directly inhibiting the mTORC1 complex. By inhibiting mTORC1, rapamycin could downregulate protein synthesis and cell growth pathways that may involve RP23-418H15.1. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAPK. If RP23-418H15.1 activity is modulated by p38 MAPK signaling, inhibition by SB203580 would lead to decreased function of RP23-418H15.1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of the JNK pathway, which might regulate RP23-418H15.1 activity if RP23-418H15.1 is a JNK pathway component or is modulated by JNK signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is another MEK inhibitor that would block the MAPK/ERK pathway, similar to PD98059, potentially leading to a decrease in RP23-418H15.1 activity if it is downstream of this pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor that could prevent activation of AKT and downstream signaling cascades, potentially affecting RP23-418H15.1 if it is a part of or regulated by the PI3K/AKT pathway. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor, which may lead to changes in cellular cytoskeleton dynamics. If RP23-418H15.1 is involved in cytoskeleton-related signaling or processes, its activity could be decreased. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor that could lead to the accumulation of ubiquitinated proteins, potentially affecting the turnover or function of RP23-418H15.1 if it is subject to proteasomal degradation. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor, potentially affecting cell cycle progression. If RP23-418H15.1 is involved in cell division or is regulated by Aurora kinase activity, this could lead to its inhibition. | ||||||